Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding

Rhea-AI Filing Summary

Allogene Therapeutics SVP and Chief Technical Officer Benjamin Beneski reported a small open-market sale of 4,835 shares of Common Stock at a weighted average price of $2.47 per share. The shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plan and were required by a “sell to cover” election, meaning the transaction was not a discretionary trade. After this sale, Beneski directly holds 198,205 shares of Allogene common stock.

Insider Trade Summary

Net Seller: 4,835 shares ($11,942)

Net Sell 1 txn

Insider Beneski Benjamin Machinas

Role SVP, Chief Technical Officer

Sold 4,835 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,835	$2.47	$12K

Holdings After Transaction: Common Stock — 198,205 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beneski Benjamin Machinas

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S		4,835(1)	D	$2.47(2)	198,205	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allogene Therapeutics (ALLO) report for Benjamin Beneski?

Allogene Therapeutics reported that SVP and Chief Technical Officer Benjamin Beneski sold 4,835 shares of common stock. The sale was executed at a weighted average price of $2.47 per share and was linked to tax withholding on restricted stock unit vesting.

Why did Allogene Therapeutics (ALLO) SVP Benjamin Beneski sell 4,835 shares?

The 4,835 shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units. Under Allogene’s equity incentive plan, these obligations are satisfied through a mandatory “sell to cover” transaction, so the sale was not a discretionary trade.

Was the Allogene Therapeutics (ALLO) insider sale by Benjamin Beneski discretionary?

No, the sale was not discretionary. The filing states the shares were sold under a mandated “sell to cover” arrangement in Allogene’s equity incentive plan, specifically to fund tax withholding on vested restricted stock units rather than reflecting an independent trading decision.

At what price did Allogene Therapeutics (ALLO) insider Benjamin Beneski sell his shares?

The Form 4 reports a weighted average sale price of $2.47 per share. Footnotes explain that the 4,835 shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, with full trade details available upon request from the company or regulators.

How many Allogene Therapeutics (ALLO) shares does Benjamin Beneski hold after this Form 4 sale?

Following the tax-related sale, Benjamin Beneski directly holds 198,205 shares of Allogene common stock. This remaining position is disclosed in the Form 4 and shows that the transaction involved only a small portion of his overall direct holdings.

What role does Benjamin Beneski hold at Allogene Therapeutics (ALLO)?

Benjamin Beneski serves as Senior Vice President and Chief Technical Officer at Allogene Therapeutics. His position is identified in the Form 4, which reports his equity transaction and clarifies that the sale was tied to tax withholding on restricted stock unit vesting.